Development of vaccine therapy for pulmonary arterial hypertension

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15440
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular medicine
• Research Institution: Mie University
• Principal Investigator: Ogihara Yoshito 三重大学, 医学部附属病院, 助教 (70626572)
• Co-Investigator(Kenkyū-buntansha): 伊藤 正明 三重大学, 医学系研究科, 教授 (00223181) ; 中神 啓徳 大阪大学, 医学系研究科, 寄附講座教授 (20325369) ; 森下 竜一 大阪大学, 医学系研究科, 寄附講座教授 (40291439) ; 土肥 薫 三重大学, 医学部附属病院, 講師 (50422837) ; 山田 典一 三重大学, 医学系研究科, リサーチアソシエイト (60303731)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 肺動脈性肺高血圧症 / ワクチン / エンドセリン-１ / IL-17A

Outline of Final Research Achievements

Endothelin-1 (ET-1) and interleukin (IL)-17A are one of the key mediators of pulmonary arterial hypertension. We developed the peptide vaccine targeting ET-1 or IL-17A. In rats, immunization with ET-1 or IL-17A vaccine successfully induced the production of anti-ET-1 antibody or anti-IL-17A antibody, respectively. We evaluated the vaccine efficacy in rat models of pulmonary hypertension. However, there was no significant differences in the pulmonary arterial pressure, the right ventricular thickness, and the degree of pulmonary vascular remodeling between the immunized rats (ET-1 or IL17-A) and the non-immunized rats.

Free Research Field

循環器内科学